Efpeglenatide is a long-acting GLP-1 receptor agonist first developed by Hanmi Pharmaceutical. Administered via weekly subcutaneous injection, it improves glycemic control, promotes weight loss, and offers significant cardiovascular and renal benefits. It is mainly evaluated for type 2 diabetes and obesity but remains an investigational drug. It is grouped under the following drug class(es): GLP‑1 Receptor Agonists. The directory classifies it as a clinical API with a peptide source/manufacturing origin. Other names for this substance include Langlenatide, efpeglenatida and efpeglenatidum. Its PubChem SID is 505586341.
Efpeglenatide
| CAS No | 1296200-77-5 |
|---|---|
| Molecular Formula | C2415H3715N663O743S17(C2H4O)n |
| Molecular Weight | 54,000 g/mol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Efpeglenatide is a long-acting GLP-1 receptor agonist first developed by Hanmi Pharmaceutical. Administered via weekly subcutaneous injection, it improves glycemic control, promotes weight loss, and offers significant cardiovascular and renal benefits.
The listed CAS number is 1296200-77-5.
The listed molecular formula is C2415H3715N663O743S17(C2H4O)n.
The listed molecular weight is 54,000 g/mol.
The source lists Langlenatide, efpeglenatida and efpeglenatidum.
It is listed under GLP‑1 Receptor Agonists.